My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Int J Cancer. 1996 Sep 27;68(1):120-5.

    Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells.

    Kandouz M, Siromachkova M, Jacob D, Chretien Marquet B, Therwath A, Gompel A.

    Laboratoire d'Oncologie Moleculaire, Universite Paris 7-Denis Diderot, France.

    Bcl-2 is a key protein involved in the control of apoptosis. Our previous studies on breast and endometrium indicated hormonal regulation of bcl-2 in these tissues. In the present work we have analyzed Bcl-2 and Bax protein expressions in MCF-7 and T47-D, 2 hormone-dependent breast-cancer cell lines, by immunoblots. Estradiol markedly increased Bcl-2 protein content, both in short- and in long-term treatments of MCF-7 cells. Two types of anti-estrogens (4-hydroxytamoxifen and RU 58668) were able to reverse this effect. Also, a synthetic progestin (ORG 2058) was able to decrease the Bcl-2 level in T47-D cells. The level of Bax protein, however, was not affected in the same conditions of hormonal treatments. The level of Bcl-2 expression was 4.5-fold higher in MCF-7 than in MDA-MB 231 (an estradiol-independent cell line). From these results, we infer the existence of hormonal regulation of Bcl-2 expression and evoke a novel role for estradiol and progestin in the genesis of breast cancer.

    PMID: 8895551 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Write to the Help Desk